Early research (Phase 1)Study completedNCT00000632
What this trial is testing
A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of 100 mcg of Env 2-3 in MF59
Who this might be right for
HIV InfectionsHIV Seronegativity
National Institute of Allergy and Infectious Diseases (NIAID) 14